The efficacy and tolerability of nebivolol in hypertensive African American patients.


Hypertensive African Americans often respond poorly to beta-blocker monotherapy, compared with whites. There is evidence, however, that suggests that this response may be different if beta-blockers with vasodilating effects are used. This 12-week, multi-center, double-blind, randomized placebo-controlled study assessed the antihypertensive efficacy and safety of nebivolol, a cardioselective, vasodilating beta1-blocker, at doses of 2.5, 5, 10, 20, or 40 mg once daily in 300 African American patients with stage I or II hypertension (mean sitting diastolic blood pressure [SiDBP] > or =95 mm Hg and < or =109 mm Hg). The primary efficacy end point was the baseline-adjusted change in trough mean SiDBP. After 12 weeks, nebivolol significantly reduced least squares mean SiDBP (P< or =.004) at all doses of 5 mg and higher and sitting systolic blood pressure (P< or =.044) at all doses 10 mg and higher, compared with placebo. The drug was safe and well-tolerated, with no significant difference in the incidence of adverse events compared with placebo. Nebivolol monotherapy provides antihypertensive efficacy, with few significant adverse effects, in hypertensive African Americans.

Citations per Year

179 Citations

Semantic Scholar estimates that this publication has 179 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Saunders2007TheEA, title={The efficacy and tolerability of nebivolol in hypertensive African American patients.}, author={Elijah B Saunders and William Bernard Smith and Karen B Desalvo and Will A Sullivan}, journal={Journal of clinical hypertension}, year={2007}, volume={9 11}, pages={866-75} }